Newsletter NGP Paper |
Publishing date: September 2021
Author(s): Boel Bengtsson (1), Christina Lindén (2), Anders Heijl (1), Sabina Andersson-Geimer (1), Johan Aspberg (1), Gauti Jóhannesson (2,3)
1 Department of Clinical Scien,ces in Malmö, Ophthalmology, Lund University, Lund, Sweden.
2 Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden.
3 Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.
PURPOSE: The aim of the study was to determine the perimetric rate of glaucoma progression in the ongoing Glaucoma Intensive Treatment Study (GITS) after 3 years of follow-up.
DESIGN: This is a randomized, two-centre, prospective open-labelled treatment trial for open-angle glaucoma (OAG).
PARTICIPANTS: The participants of this study were treatment-naive patients with newly diagnosed OAG, aged 46-78 years, with early to moderate glaucomatous visual field loss scheduled to be followed for 5 years within the study.
METHODS: Patients were randomized to initial treatment with either topical monotherapy or with an intensive approach using drugs from three different classes, plus 360° laser trabeculoplasty. Changes in treatment were allowed. Standard automated perimetry and tonometry were performed and side-effects documented. All results are presented using intention-to-treat analysis.
RESULTS: A total of 242 patients were randomized. After 3 years of follow-up, eight patients were lost to follow-up, six of whom were deceased. The median untreated baseline intraocular pressure (IOP) was 24 mmHg in both arms. The median IOP was almost constant over the 3 years of follow-up: ≈17 mmHg in the mono-arm and ≈14 mmHg in the multi-treatment arm. Treatment was intensified in 42% of the mono-treated patients and in 7% of the multi-treated patients. Treatment was reduced in 13% of the multi-treated patients. The median perimetric rate of progression was -0.5%/year in the mono-treated group and -0.1%/year in the multi-treated group (p = 0.03).
CONCLUSION: The rate of disease progression was significantly slower in the multi-treated patients than in the mono-treated patients. Further follow-up will show whether this difference is sustained over time.
© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
PMID: 34327833 DOI: 10.1111/aos.14978
Keywords: RCT; drug trial; glaucoma; progression; visual field
NGP Papers manager: Carlo Cutolo
